Avantor Expands RIM Single-Use Portfolio Across APAC
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, is expanding availability of its RIM® single-use portfolio of bioprocessing solutions across Asia Pacific (APAC). This gives biopharmaceutical manufacturers greater access to local solutions designed to support continuity of supply, efficient operations, and specific requirements that they need.

Gladys Wang, Vice President, Bioprocessing, Asia Pacific, Avantor, says: “Customers across APAC are looking for reliable single-use solutions that can support their manufacturing needs close to home. By expanding the availability of RIM solutions across the region, we are helping customers access customizable products backed by the responsiveness of regional manufacturing and the consistency of Avantor’s global quality systems.”

The RIM portfolio includes single-use consumables including bioprocessing bags, assemblies and tubing and components, as well as mixing and storage hardware, to support a range of bioprocessing applications. RIM single-use consumables are manufactured at Avantor’s Changzhou, China, facility, the company’s first single-use production plant in APAC. The 2,600-square-meter facility has more than 20 years of single-use design and manufacturing experience, is certified to ISO 9001:2015 and operates in compliance with Good Manufacturing Practice (GMP) principles.
RIM provides reliable single-use bioprocessing solutions designed to support unique process requirements, helping biomanufacturers scale with confidence. With in-region manufacturing and local component supply chains, RIM enables Avantor to support APAC customers with a more responsive supply model and right-fit solutions for their workflows. RIM products are available exclusively to customers in APAC.
For more information about RIM single-use consumables, visit corporate.avantorsciences.com/sg/en/brands/rim
About Avantor®
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, find us on LinkedIn, X (Twitter) and Facebook.
Regional Media Contact
Swati Chhabra
Manager, Corporate Communications, AMEA
Avantor
91-9958-404-334
Swati.Chhabra@avantorsciences.com
Global Media Contact
Valerie Collado
Director, Community Impact and Communications
Avantor
media@avantorsciences.com
SOURCE: Avantor and Financial News
The RIM expansion across APAC is notable for emphasizing supply continuity, since local availability of single-use bioprocessing solutions can matter as much as the proprietary technology itself for manufacturers managing complex production timelines. Gladys Wang’s framing around regional demand adds useful context. For teams summarizing updates like this, a tool such as topview t1 ai video could turn the key points into a short clip.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking localized solutions and stronger continuity of supply. The focus on efficient operations and region-specific requirements makes this especially relevant as production capacity grows across the region.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking more localized solutions and stronger continuity of supply. The focus on efficient operations and region-specific requirements should be especially valuable as production capacity grows.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these bioprocessing solutions could also reduce delays in increasingly complex production workflows.
Expanding Avantor’s RIM® single-use bioprocessing portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these solutions could be especially valuable as production capacity continues to grow across the region.
Expanding Avantor’s RIM® single-use bioprocessing portfolio across APAC should help manufacturers address regional supply-continuity needs while improving operational efficiency. Local access to solutions tailored to specific requirements is a practical step for the region’s growing biopharmaceutical sector.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these bioprocessing solutions could be especially valuable as demand for flexible, efficient manufacturing continues to grow.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking stronger continuity of supply and more efficient local operations. It’s especially valuable that the solutions are designed around the region’s specific manufacturing requirements.
Expanding the RIM® single-use portfolio across APAC is a practical step toward improving supply continuity for biopharmaceutical manufacturers. Local access to solutions tailored to regional operational requirements could help streamline bioprocessing workflows and reduce sourcing challenges.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational requirements. Local access to these bioprocessing solutions could also reduce delays and simplify procurement.
Expanding Avantor’s RIM® single-use portfolio across APAC could help biopharmaceutical manufacturers address regional supply continuity and operational needs more efficiently. Local availability is especially valuable for facilities managing time-sensitive bioprocessing workflows.
Solid experience so far. The loading times are short and the gameplay is fluid. Definitely my new go-to spot bdacc444
Solid experience so far. The loading times are short and the gameplay is fluid. Definitely my new go-to spot bdacc444
Solid experience so far. The loading times are short and the gameplay is fluid. Definitely my new go-to spot bdacc444
Best place for sports betting in my opinion. The odds are competitive and the community is awesome. Highly recommend idsobatbola
Best place for sports betting in my opinion. The odds are competitive and the community is awesome. Highly recommend idsobatbola
Expanding Avantor’s RIM single-use portfolio across APAC could help biopharmaceutical manufacturers address regional supply continuity challenges while improving operational efficiency. Local access to solutions tailored to specific manufacturing requirements is a particularly valuable step.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these bioprocessing solutions could be especially valuable as demand for flexible manufacturing continues to grow.
Expanding the RIM® single-use portfolio across APAC is a practical step toward improving supply continuity for biopharmaceutical manufacturers. Local access to solutions tailored to regional operational needs could also help reduce delays in scaling and production.
Expanding the RIM single-use portfolio across APAC could make a real difference for biopharmaceutical manufacturers managing supply continuity and regional operational requirements. Greater access to local bioprocessing solutions should also help streamline production and reduce dependence on distant supply chains.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers access localized solutions while strengthening supply continuity. It’s especially relevant for facilities balancing efficient operations with region-specific production requirements.
Expanding the RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers strengthen supply continuity while addressing region-specific operational needs. Local access to these bioprocessing solutions is a practical step toward more efficient and resilient manufacturing.
Expanding the RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers facing regional supply and operational demands. Greater access to locally available solutions could help improve continuity of supply and streamline bioprocessing operations.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking stronger supply continuity and more efficient local operations. The focus on region-specific requirements should make adoption easier across diverse markets.
Expanding the RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers address regional supply needs while improving operational efficiency. Local access to these solutions is especially valuable for maintaining continuity as production requirements grow.
Expanding the RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these bioprocessing solutions could be especially valuable for companies looking to streamline production without compromising flexibility.
Expanding Avantor’s RIM® single-use portfolio across APAC could make a meaningful difference for biopharmaceutical manufacturers managing local supply and operational requirements. Greater access to regional solutions should help strengthen continuity of supply while supporting more efficient bioprocessing.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking greater supply continuity and locally available solutions. The focus on efficient operations and region-specific requirements makes this especially relevant to the diverse needs of the market.
Expanding Avantor’s RIM® single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting region-specific operational needs. Local access to these solutions could be especially valuable as demand for flexible, efficient bioprocessing continues to grow.
Expanding the RIM single-use portfolio across APAC is a practical step for biopharmaceutical manufacturers seeking local solutions and stronger continuity of supply. It’s especially relevant for facilities balancing efficient operations with region-specific production requirements.
Expanding Avantor’s RIM single-use portfolio across APAC should help biopharmaceutical manufacturers improve supply continuity while meeting local operational requirements. Local access to these bioprocessing solutions could be especially valuable as regional production capacity continues to grow.
Expanding Avantor’s RIM® single-use portfolio across APAC is a practical step toward improving supply continuity for biopharmaceutical manufacturers. Local availability should also help facilities address region-specific production and operational requirements more efficiently.
Expanding Avantor’s RIM® single-use portfolio across APAC could help biopharmaceutical manufacturers address regional supply continuity while supporting more efficient, locally responsive operations. Availability of solutions tailored to specific manufacturing requirements is a meaningful step for the region’s growing bioprocessing sector.
Expanding Avantor’s RIM® single-use bioprocessing portfolio across APAC is a practical step toward improving supply continuity for regional biopharmaceutical manufacturers. Local access to solutions tailored to specific operational needs could also help streamline production and reduce supply-chain disruptions.